Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Benedikt Flörsch"'
Autor:
Farkhad Manapov, Alexander Nieto, Lukas Käsmann, Julian Taugner, Saskia Kenndoff, Benedikt Flörsch, Julian Guggenberger, Kerstin Hofstetter, Sophie Kröninger, Janina Lehmann, Helene Kravutske, Carolyn Pelikan, Claus Belka, Chukwuka Eze
Publikováno v:
Expert Opinion on Investigational Drugs. 32:187-200
Autor:
Lukas Käsmann, Chukwuka Eze, Julian Taugner, Alexander Nieto, Kerstin Hofstetter, Sophie Kröninger, Julian Guggenberger, Saskia Kenndoff, Benedikt Flörsch, Amanda Tufman, Niels Reinmuth, Thomas Duell, Claus Belka, Farkhad Manapov
Publikováno v:
Journal of Cancer Research and Clinical Oncology.
Purpose/aim The international standard for patients with large inoperable stage III NSCLC is durvalumab consolidation after concurrent chemoradiotherapy (CRT). In this single centre observational study based on individual data, we prospectively evalu
Autor:
Chukwuka Eze, Julian Elias Guggenberger, Nina‐Sophie Schmidt‐Hegemann, Saskia Kenndoff, Julian Taugner, Lukas Käsmann, Stephan Schönecker, Benedikt Flörsch, Minglun Li, Claus Belka, Farkhad Manapov
Publikováno v:
Cancer. 128:2358-2366
The objective of this study was to investigate the feasibility and efficacy of image-guided moderately hypofractionated thoracic radiotherapy (hypo-IGRT) in patients with non-small cell lung cancer (NSCLC) with poor performance status and severely li
Autor:
Julian Taugner, Julian Guggenberger, Farkhad Manapov, Thomas Duell, Amanda Tufman, Benedikt Flörsch, Monika Karin, Niels Reinmuth, Lukas Käsmann, Claus Belka, Chukwuka Eze, Minglun Li
Publikováno v:
Investigational New Drugs
SummaryBackground. The present study evaluates outcome after chemoradiotherapy (CRT) with concurrent and/or sequential Programmed Cell Death 1 (PD-1) or Ligand 1 (PD-L1) immune checkpoint inhibition (CPI) for inoperable stage III NSCLC patients depen
Publikováno v:
The Clinical Respiratory Journal. 15:1139-1144
Autor:
Benedikt Flörsch, Julian Taugner, Lukas Käsmann, Saskia Kenndoff, Julian Guggenberger, Amanda Tufman, Niels Reinmuth, Thomas Duell, Claus Belka, Chukwuka Eze, Farkhad Manapov
Publikováno v:
Journal of cancer research and clinical oncology.
Purpose To investigate the impact of treatment time and patterns in inoperable stage III non-small cell lung cancer (NSCLC) following concurrent chemoradiotherapy (cCRT) ± immune checkpoint inhibitors (ICIs). Methods Patients were stratified by trea
Autor:
Lukas Käsmann, Julian Taugner, Chukwuka Eze, Alexander Nieto, Carolyn Pelikan, Benedikt Flörsch, Saskia Kenndoff, Thomas P. Hofer, Elfriede Nössner, Christian Schulz, Marcus Unterrainer, Amanda Tufman, Frederick Klauschen, Andreas Jung, Jens Neumann, Jörg Kumbrink, Niels Reinmuth, Peter Bartenstein, Claus Belka, Farkhad Manapov
Publikováno v:
Transl. Lung Cancer Res. 11, 1503-1509 (2022)
Background: Concurrent platinum-based chemoradiotherapy (CRT) followed by durvalumab maintenance treatment represents the new standard of care in unresectable stage III non-small cell lung cancer (NSCLC). In this prospective hypothesis-generating sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::661b3aa717169d434839667f27d1df91
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=65577
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=65577
Autor:
Benedikt Flörsch, Julian Taugner, Lukas Käsmann, Saskia Kenndoff, Julian Guggenberger, Amanda Tufman, Niels Reinmuth, Thomas Duell, Claus Belka, Chukwuka Eze, Farkhad Manapov
Publikováno v:
Journal of Clinical Oncology. 40:e20578-e20578
e20578 Background: To investigate the impact of treatment patterns in inoperable stage III NSCLC following concurrent chemoradiotherapy with or without immune checkpoint inhibition (cCRT±ICI). Methods: Patients were stratified by treatment year and
Autor:
Lukas Käsmann, Julian Taugner, Chukwuka Eze, Julian Guggenberger, Saskia Kenndoff, Benedikt Flörsch, Amanda Tufman, Niels Reinmuth, Claus Belka, Farkhad Manapov
Publikováno v:
Journal of Clinical Oncology. 40:e20589-e20589
e20589 Background: Durvalumab maintenance treatment after completion of concurrent chemoradiotherapy (CRT) in patients with inoperable stage III NSCLC is the international standard. In this propensity-matched analysis, we prospectively evaluated the
Autor:
Julian Taugner, Lukas Käsmann, Chukwuka Eze, Alexander Nieto, Julian Guggenberger, Benedikt Flörsch, Saskia Kenndoff, Amanda Tufman, Niels Reinmuth, Claus Belka, Farkhad Manapov
Publikováno v:
Journal of Clinical Oncology. 40:e20570-e20570
e20570 Background: We compared pattern of failure in patients treated with chemoradiotherapy (CRT) with concurrent and/or sequential Programmed Cell Death 1 (PD-1) or Ligand 1 (PD-L1) immune checkpoint inhibition (IO, immuno-oncology therapy) and CRT